SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that a phase 2a study of NU1618, the company’s lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia.
